Heart failure with systolic dysfunction complicating acute myocardial infarction – differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial  by Carillo, Sylvain et al.
Archives of Cardiovascular Disease (2014) 107, 149—157
Available  online  at
ScienceDirect
www.sciencedirect.com
CLINICAL RESEARCH
Heart  failure  with  systolic  dysfunction
complicating  acute  myocardial
infarction  —  differential  outcomes  but
similar  eplerenone  efﬁcacy  by  ST-segment
or  non-ST-segment  elevation:  A  post  hoc
substudy  of  the  EPHESUS  trial
Insufﬁsance  cardiaque  systolique  post-infarctus  du  myocarde  —  un
pronostic  différent  mais  une  efﬁcacité  similaire  de  l’éplérénone
chez  les  patients  avec  ou  sans  sus-décalage  du  segment  ST  :  une
sous-étude  post  hoc  d’EPHESUS
Sylvain  Carilloa,∗,  Yan  Zhangb,  Renaud  Faya,
Michael  Angioi c,  John  Vincentd,
Santosh  C.  Sutradhord,  Ali  Ahmedb,
Bertram  Pitte,  Faiez  Zannada
a Inserm  U961,  cardiology,  centre  d’investigations  cliniques  CIC9501,  institut  Lorrain  du  cœur
et des  vaisseaux,  CHU  de  Nancy,  2,  avenue  du  Morvan,  54500  Vandoeuvre-Lès-Nancy,  France
b University  of  Alabama  at  Birmingham  and  VA  medical  center,  Birmingham,  AL,  USA
c Clinic  Louis-Pasteur,  54270  Essey-Lès-Nancy,  France
d Pﬁzer  Inc.,  New  York  City,  NY,  USA
e University  of  Michigan,  Ann  Arbor,  MI,  USAReceived  20  October  2013;  received  in  revised  form  18  January  2014;  accepted  21  January  2014
Available online  11  March  2014
Abbreviations: ACS, Acute coronary syndrome; AMI, Acute myocardial infarction; CI, Conﬁdence interval; EPHESUS, Eplerenone Post-
Acute Myocardial Infarction Heart Failure Efﬁcacy and Survival Study; GRACE, Global Registry of Acute Coronary Events; HF, Heart failure;
HR, Hazard ratio; LVEF, Left ventricular ejection fraction; LVSD, Left ventricular systolic dysfunction; NSTEMI, Non-ST-segment elevation
myocardial infarction; PS, Propensity score; STEMI, ST-segment elevation myocardial infarction.
∗ Corresponding author.
E-mail address: s.carillo@chu-nancy.fr (S. Carillo).
1875-2136/$ — see front matter © 2014 Elsevier Masson SAS. All rights reserved.
http://dx.doi.org/10.1016/j.acvd.2014.01.010
150  S.  Carillo  et  al.
KEYWORDS
NSTEMI;
STEMI;
Heart  failure;
Eplerenone
Summary
Background.  —  Differential  outcomes  in  patients  with  acute  systolic  heart  failure  (HF)  com-
plicating acute  myocardial  infarction  (AMI)  and  the  efﬁcacy  of  mineralocorticoid  receptor
antagonists  according  to  non-ST-segment  and  ST-segment  elevation  myocardial  infarction
(NSTEMI, STEMI)  status  has  not  been  speciﬁcally  investigated.
Methods.  —  In  the  EPHESUS  study,  6632  patients  with  acute  HF  and  left  ventricular  ejection  frac-
tion <  40%  were  randomized  3—14  days  post-AMI  (median  7.3  ±  3.0  days)  to  receive  eplerenone
(n =  3319)  or  placebo  (n  =  3313).  Among  them,  6392  patients  with  available  data  on  baseline  ST-
segment  status  (4634  STEMI;  1758  NSTEMI)  were  compared  using  a  Cox  model  analysis  stratiﬁed
according  to  quintiles  of  propensity  score  (PS),  taking  into  account  major  baseline  risk  factors,
including revascularization.
Results.  —  STEMI  and  NSTEMI  patients  differed  signiﬁcantly  across  a  large  variety  of  base-
line characteristics.  During  30  months  of  follow-up,  all-cause  death  occurred  in  19%  and
13% (P  <  0.0001),  cardiovascular  death  in  16%  and  12%  (P  <  0.0001),  cardiovascular  death  and
hospitalization  in  33%  and  26%  (P  <  0.0001)  and  death  from  progression  of  HF  in  5%  and  3%
(P <  0.0001)  of  unadjusted  NSTEMI  and  STEMI  patients,  respectively.  After  Cox  model  PS  adjust-
ment without  revascularization,  NSTEMI  status  still  proved  to  be  a  risk  factor  for  all-cause
death, cardiovascular  death  and  death  from  progression  of  HF.  After  Cox  model  PS  adjust-
ment including  revascularization,  none  of  the  outcomes  differed  between  STEMI  and  NSTEMI
patients. Eplerenone  morbidity  and  mortality  beneﬁts  were  consistent  in  the  STEMI  and  NSTEMI
subgroups.
Conclusion.  —  In  patients  with  acute  systolic  HF  complicating  AMI,  eplerenone  improves  out-
comes equally  in  STEMI  and  NSTEMI  patients.  Worse  outcomes  associated  with  NSTEMI  could  be
explained by  more  co-morbidities,  less  aggressive  therapies  and,  mainly,  less  frequent  revas-
cularization.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  — Le  pronostic  des  patients  en  insufﬁsance  cardiaque  (IC)  systolique  aiguë  post-
infarctus  du  myocarde  (IDM),  ainsi  que  l’efﬁcacité  des  antagonistes  des  récepteurs  aux
minéralocorticoïdes  en  fonction  de  l’élévation  (ST  +  )  ou  non  (ST—)  du  segment  ST  n’a  pas
encore été  étudiée  de  manière  spéciﬁque.
Méthodes.  — Dans  l’étude  EPHESUS,  6632  patients  en  IC  aiguë  avec  une  fraction  d’éjection  <  40  %
ont été  randomisés  entre  j3  et  j14  post-IDM  (médiane  de  7,3  ±  3,0  jours)  pour  recevoir  de
l’éplérénone  (n  =  3319)  ou  un  placebo  (n  =  3313).  Parmi  eux,  les  6392  patients  ayant  des  don-
nées exploitables  sur  l’état  du  segment  ST  à  la  phase  aiguë  de  l’IDM  (4634  ST+  et  1758  ST—)  ont
été analysés  selon  le  modèle  de  Cox  stratiﬁé  par  quintiles  de  score  de  propensité  prenant  en
compte les  principales  données,  y  compris  le  taux  de  revascularisation,  différent  de  manière
signiﬁcative  entre  les  groupes  ST+  et  ST—.
Résultats.  —  Au  terme  des  30  mois  de  suivi  de  l’étude,  l’analyse  sans  ajustement  par  score  de
propensité  retrouve  un  pronostic  plus  péjoratif  pour  les  ST—,  avec  des  taux  de  décès  toute
cause de  19  %  vs  13  %  (p  <  0,0001),  de  décès  cardiovasculaire  de  16  %  vs  12  %  (p  <  0,0001),  de
décès cardiovasculaire/hospitalisation  cardiovasculaire  de  33  %  vs  26  %  (p  <  0,0001)  et  de  décès
par IC  de  5  %  vs  3  %  (p  <  0,0001)  observés  respectivement  chez  les  ST—  et  les  ST+.  Après  ajuste-
ment par  quintiles  de  score  de  propensité  sans  tenir  compte  du  taux  de  revascularisation,  le
statut ST—  demeure  plus  péjoratif  puisqu’il  est  un  facteur  de  risque  de  décès  toute  cause,  décès
cardiovasculaire  et  décès  par  insufﬁsance  cardiaque.  Le  fait  d’inclure  le  taux  de  revasculari-
sation à  l’analyse  précédente  abolit  totalement  la  différence  de  pronostic  entre  les  patients
ST— et  ST+.  Par  ailleurs,  les  bénéﬁces  de  l’administration  d’éplerénone  mesurés  en  termes  de
morbidité  et  de  mortalité  sont  identiques  chez  les  patients  ST—  et  ST+.
Conclusions.  —  Chez  les  patients  en  IC  systolique  aiguë  post-IDM,  le  bénéﬁce  lié  à
l’administration  d’éplérénone  est  identique  chez  les  ST—  et  les  ST+.  Le  pronostic  plus  défavor-
able observé  chez  les  ST—  s’explique  par  des  comorbidités  plus  importantes,  des  traitements
médicamenteux  moins  agressifs,  mais  surtout  un  taux  de  revascularisation  plus  faible.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Background
Nearly  half  of  all  patients  with  acute  myocardial  infarction
(AMI)  present  left  ventricular  systolic  dysfunction  (LVSD)  and
one  quarter  show  symptoms  of  heart  failure  (HF),  both  of
which  are  associated  with  poor  outcomes  [1—6].  Neverthe-
less,  the  Global  Registry  of  Acute  Coronary  Events  (GRACE)
has  shown  that  the  spread  of  evidence-based  therapies  and
myocardial  revascularization  has  halved  the  rate  of  HF  dur-
ing  AMI  [2].  Still,  this  complication  remains  challenging,
as  80%  of  morbidity  and  mortality  in  the  acute  phase  of
myocardial  infarction  is  to  be  found  in  this  subgroup  [7,8].
Regardless  of  LVSD  or  HF,  there  are  clear  prognostic  dif-
ferences  between  patients  with  non-ST-segment  elevation
myocardial  infarction  (NSTEMI)  and  those  with  ST-segment
elevation  myocardial  infarction  (STEMI).  Indeed,  hospital
prognosis  is  known  to  be  better  for  NSTEMI  patients  [9—11],
whereas  long-term  prognosis  is  described  as  better  for  STEMI
patients  [10,12,13].
Aldosterone  is  a  mediator  of  the  renin-angiotensin-
aldosterone  system,  which  is  known  to  produce  adverse
cardiovascular  effects  in  post-AMI  patients,  such  as  left  ven-
tricle  remodelling  and  endothelial  dysfunction  [14].  The
Eplerenone  Post-Acute  Myocardial  Infarction  Heart  Failure
Efﬁcacy  and  Survival  Study  (EPHESUS)  [15]  conducted  in
post-AMI  patients  complicated  by  acute  HF  and  LVSD,  showed
that  the  mineralocorticoid  receptor  antagonist  eplerenone
improved  morbidity  and  mortality  outcomes.
Different  outcomes  in  patients  with  acute  HF  and  LVSD
complicating  AMI  and  the  efﬁcacy  of  mineralocorticoid
receptor  antagonists  depending  on  NSTEMI  and  STEMI  sta-
tus  has  not  been  speciﬁcally  investigated.  In  EPHESUS,
AMI  patients  complicated  by  LVSD  and  receiving  standard
medical  therapy  were  randomized  to  eplerenone  versus
placebo.  In  the  current  analysis,  we  compared  outcomes  and
eplerenone  beneﬁts  depending  on  NSTEMI  and  STEMI  status,
using  a  propensity  score  (PS)-adjusted  Cox  model.
Methods
Study design
EPHESUS  was  an  international  randomized  double-blind
placebo-controlled  clinical  trial,  the  design  and  results  of
which  have  been  previously  reported  [15].  Brieﬂy,  6632
hospitalized  post-AMI  patients  with  left  ventricular  ejec-
tion  fraction  (LVEF)  ≤  40%  were  randomized  within  3  to  14
days  (median  7.3  ±  3.0  days)  post-AMI  to  receive  either
eplerenone  (mean  dose  43  mg/day)  or  placebo  during  the
2000—2001  period.  LVEF  was  measured  and  analysed  at  the
study  site  by  echocardiography,  radionuclide  angiography
or  left  angiography.  Revascularization  was  performed  using
thrombolysis,  percutaneous  coronary  angioplasty  and/or
coronary  artery  bypass  grafting.  All  patients  received
standard  medical  therapy  and  most  had  HF  symptoms,
diagnosed  clinically  by  the  presence  of  pulmonary  rales,
a  third  heart  sound  or  pulmonary  vascular  congestion  on
chest  radiography.  However,  patients  without  HF  symptoms
could  be  enrolled  if  they  had  diabetes.  Overall,  2142  (33%)
patients  had  diabetes,  among  whom  659  (10%  of  all  patients
and  31%  of  all  diabetics)  had  no  HF  symptoms.  Patients  were
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ollowed  for  up  to  2.5  years,  with  a  mean  16-month  follow-
p.
tudy patients
f  the  6632  EPHESUS  participants,  6510  (98%)  had  data  on
T-segment  status.  These  patients  were  classiﬁed  as  having
STEMI  or  STEMI  by  the  study  investigators,  based  on  their
nterpretation  of  the  electrocardiogram;  118  were  excluded
rom  the  analysis  due  to  missing  values  for  the  20  selected
aseline  variables  used  for  PS-matching.  Therefore,  obser-
ations  from  6392  subjects  (1758  [27%]  NSTEMI;  4634  [73%]
TEMI)  were  used  for  the  analysis.  Data  on  sociodemo-
raphic,  clinical,  subclinical  and  laboratory  variables  were
ollected  at  baseline  and  have  been  reported  previously
15].
tudy outcomes
rimary  outcomes  of  interest  for  the  current  analysis  were
ll-cause  death,  cardiovascular  death,  cardiovascular  death
r  hospitalization  and  death  from  progression  of  HF  during
he  2.5  years  of  follow-up.  These  events  were  adjudicated
y  a  blinded  EPHESUS  critical  events  committee  [15].
We  examined  the  association  of  eplerenone  treatment
ith  primary  outcomes  of  interest,  depending  on  ST-
egment  status.
tatistical analyses
ll  analyses  were  performed  using  SAS  9.2  (SAS  Institute
nc.,  Cary,  NC,  USA).  The  two-tailed  signiﬁcance  level
as  set  at  P  <  0.05.  Continuous  variables  are  expressed
s  means  ±  standard  deviations,  categorical  variables  as
requencies  and  percentages  and  hazard  ratios  (HRs)  as  esti-
ates  and  95%  conﬁdence  intervals  (CIs).  Comparisons  of
aseline  characteristics  were  carried  out  using  the  Mann-
hitney  U  test  and  Pearson’s  Chi2 test,  as  appropriate.
The  association  of  eplerenone  and  NSTEMI  with  four
elected  outcomes  (all-cause  death,  cardiovascular  death,
ardiovascular  death  or  cardiovascular  hospitalization  and
eath  from  progression  of  HF)  was  analysed  using  the  Cox
roportional  hazards  model.  STEMI  and  NSTEMI  patients  dif-
ered  signiﬁcantly  in  a  number  of  features:  using  logistic
egression,  a  PS  was  constructed  as  the  probability  of  an
ndividual  to  present  NSTEMI  based  on  the  20  selected  base-
ine  characteristics  presented  in  Table  1. Two  separate  PSs
ere  computed  separately,  including  or  not  including  revas-
ularization,  in  order  to  investigate  its  effect  on  prognosis.
 sensitivity  analysis  was  done  using  PS-matching,  according
o  all  64  available  baseline  characteristics.
Time-to-event  analyses  were  then  carried  out  with
plerenone  and  NSTEMI  as  exposition  factors  and  PS  quin-
iles  as  stratiﬁcation  variables,  which  allowed  the  number
f  factors  in  the  model  to  be  reduced  and  prevented  any
ssue  of  log-linearity  between  PS  and  outcomes.  The  validity
ssumptions  of  the  Cox  models  (proportionality  of  hazards,
bsence  of  interaction  and  co-linearity)  were  thoroughly
hecked  and  any  violation  was  ruled  out.  The  association  of
plerenone  with  outcomes  according  to  ST-segment  status
as  illustrated  using  Kaplan—Meier  curves.
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Table  1  Baseline  characteristics.
NSTEMI  (n  =  1758)  STEMI  (n  =  4634)  Pa
n  Mean  ±  SD  or  %  n  Mean  ±  SD  or  %
Region
North  America  403  23  384  8  <  0.0001
Western  Europe  428  24  1198  26
Eastern  Europe  669  38  2210  48
Latin  America  100  6  456  10
Other  158  9  386  8
Demographics
Men  1194  68  3350  72  0.0006
Age  (years) 1758  66.9  ±  11.1  4634  62.6  ±  11.4  <  0.0001
Risk  factors
Body  mass  index  (kg/m2)  1758  27  ±  5  4634  27  ±  4  0.86
History  of  hypertension  1196  68  2661  57  <  0.0001
Diabetes  714  41  1330  29  <  0.0001
Prior  history  of  AMI 775  44  928  20  <  0.0001
Prior  episode  of  HF 496  28  394  9  <  0.0001
Haemodynamics
Systolic  blood  pressure  (mmHg)  1758  122.5  ±  17.0  4634  117.7  ±  16.0  <  0.0001
Heart  rate  (bpm)  1758  73  ±  12  4634  75  ±  12  <  0.0001
LVEF  (%)  1758  32.5  ±  6.5  4634  33.5  ±  7.7  <  0.0001
Biology
Haemoglobin  (g/dL)  1758  13.3  ±  1.8  4634  13.3  ±  1.7  0.67
Serum  creatinine  (mmol/L)  1758  104.2  ±  31.7  4634  97.6  ±  27.4  <  0.0001
Treatments
Revascularization  464  26  2463  53  <  0.0001
ACEI  1473  84  3945  85  0.18
ARB  72  4  128  3  0.006
Beta-blocker  1281  73  3510  76  0.018
Aspirin  1519  86  4143  89  0.0008
Statin  815  46  2146  46  0.97
Study  drug
Eplerenone  839  48  2365  51  0.018
ACEI: angiotensin-converting enzyme inhibitor; AMI: acute myocardial infarction; ARB: angiotensin II receptor antagonist; bpm: beats
per minute; HF: heart failure; LVEF: left ventricular ejection fraction; NSTEMI: non-ST-segment elevation myocardial infarction; SD:
standard deviation; STEMI: ST-segment elevation myocardial infarction.
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atient characteristics
 signiﬁcant  proportion  of  the  patients  had  NSTEMI  (1758
f  6392  patients,  27%).  Before  matching,  compared  with
TEMI  patients,  those  with  NSTEMI  came  from  different
egions,  were  older,  were  more  frequently  women  and
ad  a  higher  burden  of  co-morbidities,  such  as  hyperten-
ion,  diabetes,  prior  history  of  AMI  and  prior  episode  of
F  (Table  1).  NSTEMI  patients  had  a  lower  heart  rate,
igher  systolic  blood  pressure  and  a  lower  LVEF  and  more
requently  had  impaired  renal  function  (Table  1).  Concern-
ng  therapies,  NSTEMI  patients  less  frequently  received
spirin  and  beta-blockers,  were  more  frequently  given
ngiotensin  receptor  therapy  and  were  far  less  frequently
a
d
d
Prical variables, respectively.
evascularized.  NSTEMI  patients  received  eplerenone
Table  1).
utcomes according to ST segment status
ver  the  30-month  follow-up  period,  compared  with  STEMI
atients,  NSTEMI  patients  experienced  more  adverse  out-
omes  (all-cause  death,  19%  vs  13%;  cardiovascular  death,
6%  vs  12%;  cardiovascular  death/hospitalization,  33%  vs
6%;  and  death  from  progression  of  HF,  5%  vs  3%)  (Table  2).
After  Cox  model  PS  adjustment  without  revasculariza-
ion,  NSTEMI  status  still  proved  to  be  a  risk  factor  for
ll-cause  death  (HR  1.18,  95%  CI  1.03—1.37;  P  =  0.022),  car-
iovascular  death  (HR  1.17,  95%  CI  1.00—1.37;  P  =  0.048)  and
eath  from  progression  of  HF  (HR  1.36,  95%  CI  1.01—1.82;
 =  0.042)  (Table  3).
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Table  2  Outcomes.
NSTEMI  (na =  1758)  STEMI  (na =  4634)  Pb
nc %  nc %
All-cause  death  340  19  621  13  <  0.0001
Cardiovascular  death  290  16  538  12  <  0.0001
Cardiovascular  death  or  hospitalization 583  33  1188  26  <  0.0001
Death  from  progression  of  HF 92  5  122  3  <  0.0001
HF: heart failure; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: ST-segment elevation myocardial infarction.
a Total frequency.
b P value from Chi2 test.
c Outcome frequency.
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tion,  none  of  the  outcomes  differed  between  STEMI  and
NSTEMI  patients  (Table  4).
Eplerenone efﬁcacyThe  beneﬁcial  effect  of  eplerenone  was  constant  among  all
primary  outcomes  of  interest  (Table  5)  and  was  observed
whatever  the  ST  segment  status  (Fig.  1).
Table  3  Association  of  ST-segment  status  with  out-
comes  (propensity  score  without  revascularization).
NSTEMI
Pa HR  (95%  CI)
All-cause  death  0.022  1.18  (1.03—1.37)
Cardiovascular  death  0.048  1.17  (1.00—1.37)
Cardiovascular  death  or
hospitalization
0.29  1.06  (0.95—1.18)
Death  from  progression
of HF
0.042  1.36  (1.01—1.82)
CI: conﬁdence interval; HF: heart failure; HR: hazard ratio;
NSTEMI: non-ST-segment elevation myocardial infarction.
a P value from Cox regression.
Table  4  Association  of  ST-segment  status  with  out-
comes  (propensity  score  with  revascularization).
NSTEMI
Pa HR  (95%  CI)
All-cause  death  0.28  1.08  (0.94—1.25)
Cardiovascular  death  0.45  1.06  (0.91—1.24)
Cardiovascular  death  or
hospitalization
0.79  1.02  (0.91—1.13)
Death  from  progression
of HF
0.15 1.25  (0.93—1.68)
CI: conﬁdence interval; HF: heart failure; HR: hazard ratio;
NSTEMI: non-ST-segment elevation myocardial infarction.
a P value from Cox regression.
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miscussion
o  our  knowledge,  this  study  is  the  ﬁrst  to  focus  on  the  pro-
nostic  differences  between  NSTEMI  and  STEMI  speciﬁcally
n  patients  with  systolic  acute  HF  complicating  AMI,  a  sub-
et  of  patients  at  the  highest  risk  of  short-  and  long-term
eath  [5,6,8].  Consistent  with  the  main  ﬁndings  of  previous
eports  in  non-HF  patients  [8,10,13,16,17],  worse  outcomes
ssociated  with  NSTEMI  could  mainly  be  explained  by  more
requent  co-morbidities,  less  aggressive  therapies  and,  most
mportantly,  less  frequent  revascularization.  A  second  major
nding  of  our  analysis  is  that  eplerenone  improved  out-
omes  in  both  STEMI  and  NSTEMI  patients.  Although  STEMI
nd  NSTEMI  go  through  the  same  pathophysiological  process,
amely  acute  atherothrombosis  [18—20], there  are  differ-
nces  between  the  two  presentations.
STEMI  is  the  consequence  of  complete  thrombotic  occlu-
ion  of  a  major  coronary  artery,  mainly  by  plaque  disruption
21], whereas  NSTEMI  is  a  subtotal  coronary  occlusion,
ainly  by  plaque  erosion  [22]. Thrombus  is  described  as
brin  rich  in  STEMI  and  platelet  rich  in  NSTEMI.  Thrombotic
oad  is  often  higher  in  STEMI  than  in  NSTEMI  [23,24].
Regarding  HF,  myocyte  loss  leading  to  acute  contractile
ysfunction  is  not  the  only  mechanism  leading  to  acute
F  in  acute  coronary  syndrome  (ACS)  patients,  as  the
RACE  registry  showed  that  11.2%  of  patients  with  unsta-
le  angina  also  showed  signs  of  HF  [3].  Thus,  myocardial
tunning/hibernation  [6], ventricular  remodelling,  acute
itral  regurgitation  and  ischaemia-induced  impairment  in
Table  5  Association  of  study  drug  with  outcomes.
Eplerenone
Pa HR  (IQR)
All-cause  death  0.004  0.83  (0.73—0.94)
Cardiovascular  death  0.003  0.81  (0.71—0.93)
Cardiovascular  death  or
hospitalization
0.004  0.87  (0.79—0.96)
Death  from  progression
of  HF
0.049  0.76  (0.58—1.00)
HF: heart failure; HR: hazard ratio; IQR: interquartile range.
a P value from Cox regression.
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tigure 1. Association of eplerenone with outcomes according to 
yocardial  relaxation  [5]  have  been  reported  to  cause  HF  in
cute  ischaemic  conditions.
oor prognosis of post-AMI patients with acute
ystolic HF
F  complicating  AMI  is  known  to  increase  cardiovascular
isk  in  equal  proportions  among  STEMI  and  NSTEMI  patients,
hile  HF  AMI  patients  are  known  to  beneﬁt  from  revascu-
arization  less  frequently  than  non-HF  patients  [3].  In  the
RACE  [3],  NRMI-2  [8],  Euro  Heart  Survey  [11]  and  Gulf  RACE
25]  registries,  conducted  in  unselected  ACS  patients,  the
eath  rate  in  patients  with  HF  was  2—4  times  higher  than
n  those  without  HF.  Our  results  obtained  in  acute  systolic
F  patients  show  once  again  that  acute  HF  seriously  com-
ounds  the  prognosis  of  AMI  patients  and  illustrates  very  well
he  concept  of  ‘‘deadly  intersection’’  between  ACS  and  HF
entioned  by  Velasquez  and  Pfeffer  [5].
Acute  clinical  HF  and  LVSD  are  two  phenomena  that  do
ot  necessarily  co-exist  in  post-AMI  patients.  Indeed,  in  the
AVE  study  [26],  60%  of  LVSD  patients  showed  no  HF,  whereas
n  the  VALIANT  study  [27],  42%  of  patients  with  acute  HF
L
H
zgment status.
id  not  have  LVSD.  In  our  study,  post-AMI  patients  with  both
linical  signs  of  HF  and  LVSD  were  enrolled,  thus  we  targeted
he  highest  risk  patients.
As  could  be  expected,  the  prognosis  of  our  post-AMI
atients  with  acute  systolic  HF  was  very  poor,  with  a  19%-
ate  of  all-cause  death  for  NSTEMI  patients  and  a  16%-rate
or  STEMI  patients  over  the  2.5-year  follow-up  period.  The
ajority  of  these  deaths  were  due  to  cardiovascular  causes.
Given  that  the  patients  in  our  study  had  a  poor  out-
ome,  we  must  wonder  about  the  medical  and  reperfusion
herapies  that  could  have  improved  their  prognosis.  Con-
erning  medical  therapies,  both  our  NSTEMI  and  STEMI
roups  were  quite  adequately  treated,  in  compliance  with
he  guidelines  at  the  time  of  the  study:  73—86%  were
reated  with  beta-blockers,  angiotensin-converting  enzyme
nhibitors  and  aspirin.  The  relatively  low  use  of  statins  is
onsistent  with  their  low  level  of  evidence  in  post-AMI  HF
atients  at  the  time  of  the  trial.  Indeed,  so  far,  all  statin
rials  in  ACS  patients  have  excluded  those  with  HF  and/or
VSD.
Although  at  the  time  of  the  study  NSTEMI  and  STEMI  with
F  were  both  a  class  1  indication  for  urgent  revasculari-
ation  [28,29],  only  26%  and  53%,  respectively,  received
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reperfusion  therapy  —  a  low  rate  in  line  with  a  worldwide
study  and  with  clinical  practice  in  the  early  2000s  [13,30].
The  recent  spread  of  reperfusion  therapies  is  the  main  fac-
tor  associated  with  the  recent  improvement  in  outcomes
among  AMI  patients  [2].  In  comparison,  the  latest  registry
in  Europe  has  shown  that  90%  of  STEMI  patients  and  70%
of  NSTEMI  patients  beneﬁt  from  revascularization  nowa-
days  [31].  Consequently,  more  frequent  use  of  reperfusion
therapies  among  our  high-risk  AMI  HF  patients  would  have
improved  outcome  in  both  our  NSTEMI  and  STEMI  subgroups.
Differences between NSTEMI and STEMI among
HF patients
Although  in  unselected  ACS  patients  NSTEMI  is  as  common  as
STEMI  [11],  our  study  enrolled  fewer  NSTEMI  patients  than
STEMI  patients,  probably  because  of  the  per-protocol  selec-
tion  criterion  of  LVSD  and  HF,  which  is  indeed  more  frequent
in  STEMI  patients  [9,12,13].
Previous  studies  have  already  shown  that  although
NSTEMI  causes  less  severe  ischaemia  and  myocardial  dam-
age,  it  is  usually  associated  with  a  worse  outcome  than  STEMI
[10,12,13];  a  combination  of  ﬁve  factors  may  account  for
this.
First,  as  shown  in  Tables  1  and  4,  revascularization  is  the
most  discriminating  factor  between  STEMI-HF  and  NSTEMI-
HF  patients,  with  twice  as  many  reperfusion  therapies  in
STEMI  patients.  Indeed,  our  analysis  showed  that  the  pro-
gnostic  difference  between  the  two  groups  was  no  longer
statistically  signiﬁcant  when  revascularization  was  taken
into  account  in  the  adjustment  strategy.  However,  even  if
NSTEMI  patients  beneﬁt  more  frequently  from  revasculariza-
tion  nowadays,  they  still  are  more  unlikely  to  be  reperfused
than  STEMI  patients  (70%  vs  90%)  [31].  This  persistent  dif-
ference  is  probably  due  to  a  combination  of  technical  and
individual  factors.  Indeed,  a  signiﬁcant  proportion  of  NSTEMI
patients  are  not  technically  suitable  for  revascularization,
as  they  more  frequently  present  a  diffuse  coronary  disease
with  fewer  fresh  thrombi  and  more  calciﬁed  lesions  than
STEMI  patients.  Moreover,  NSTEMI  patients  are  still  less  fre-
quently  revascularized  than  STEMI  patients  because  of  a
perceived  lower  beneﬁt  in  such  patients.  A  more  frequent
use  of  revascularization  among  our  speciﬁc  very-high-risk
NSTEMI-HF  patients  at  the  time  of  the  study  might  have
improved  their  prognosis  [2]  and  decreased  the  difference
in  outcomes  between  NSTEMI  and  STEMI.
Second,  due  to  study  design,  patients  who  died  within
3  days  after  AMI  (i.e.  before  enrolment  in  the  trial)  were
not  included  in  our  study.  Unlike  NSTEMI  patients,  >  50%  of
deaths  in  STEMI  patients  occur  very  early  after  the  onset
of  symptoms,  especially  during  the  ﬁrst  2  hours  [33].  The
selection  bias  related  to  enrolment  time  might  have  under-
estimated  the  mortality  rate  in  the  STEMI  subgroup,  which
partly  explains  the  mortality  difference  between  NSTEMI  and
STEMI  patients  in  our  report.
Third,  our  NSTEMI  patients  were  less  likely  to  receive
appropriate  medical  therapies,  such  as  aspirin  and  beta-
blockers,  when  hospitalized  for  AMI.  This  less  rigorous
medical  treatment  of  NSTEMI  patients  has  been  consistently
reported  in  previous  studies  as  a  factor  that  might  explain
their  worse  prognosis  compared  with  STEMI  patients  [34].
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Fourth,  compared  with  STEMI  patients,  those  with  NSTEMI
ad  a  greater  burden  of  co-morbidities,  such  as  old  age,
iabetes  and  hypertension.  Studies  carried  out  regardless  of
F  status,  such  as  EHS-ACS  II  [11]  and  the  series  reported  by
erkelsen  et  al.  [13], came  to  strictly  similar  ﬁndings.
Fifth,  compared  with  STEMI  patients,  our  NSTEMI  patients
ere  three  times  more  likely  to  have  a  history  of  HF,  a
ondition  that  is  known  to  triple  the  long-term  risk  of  death
fter  myocardial  infarction  [13]  and  inevitably  affected  the
rognosis  of  NSTEMI  patients  in  our  series.
Consequently,  as  can  be  seen  in  unselected  AMI  patients
35], it  seems  that  the  poor  long-term  outcome  in  our
STEMI-HF  patients  can  be  explained  by  more  frequent
o-morbidities  and  less  aggressive  treatment  (mainly  less
requent  revascularization),  rather  than  by  the  type  of  acute
T-segment  variation  per  se.
Thus,  the  imbalances  in  baseline  characteristics  men-
ioned  above  account  for  the  less  favourable  unadjusted
rognosis  among  NSTEMI  patients,  as  illustrated  by  the
esults  of  our  PS-matching  analysis,  which  abolished  all  dif-
erences  in  primary  outcomes  between  NSTEMI  and  STEMI
atients.
plerenone efﬁciency
n  the  EPHESUS  study,  eplerenone  beneﬁted  patients  with
STEMI  and  STEMI  equally.  Indeed,  whatever  the  ST-segment
tatus,  high-risk  AMI  survivors  with  LVSD  or  HF,  receiv-
ng  optimal  treatment  with  angiotensin-converting  enzyme
nhibitors  or  angiotensin  receptor  blockers  and  a  beta-
locker  beneﬁt  from  further  neurohormonal  blockade  with
plerenone.
Although  post  hoc,  this  new  subgroup  analysis  extends
he  ﬁndings  of  previous  reports  of  prespeciﬁed  or  post  hoc
ubgroup  analyses,  such  as  diabetics  [36], hypertensives  [37]
nd  patients  with  LVEF  <  30%  [38],  which  consistently  showed
 marked  clinical  beneﬁt  for  eplerenone  across  a  variety  of
MI  presentations.
tudy limitations
everal  limitations  to  our  study  must  be  acknowledged.
aseline  electrocardiographical  ﬁndings  of  STEMI  or  NSTEMI
ere  reported  by  investigators  and  were  not  centrally  adju-
icated,  therefore  misclassiﬁcation  is  possible.  It  is  also
ossible  that  patients  with  STEMI  developed  NSTEMI,  or  vice
ersa,  during  follow-up.  However,  this  phenomenon,  also
nown  as  regression  dilution,  is  known  to  underestimate  true
ssociations  [39].
Based  on  pathophysiological  hypothesis  and  prognostic
iterature  data,  we  selected  20  baseline  characteristics
hat  differed  most  between  the  two  groups  to  run  our  PS
djustment.  Using  all  available  characteristics  would  have
liminated  all  identiﬁable  baseline  confounders,  but  would
ave  seriously  lowered  the  power  of  our  analysis.  A  sensi-
ivity  analysis  using  PS-matching  all  64  available  baseline
ariables  yielded  similar  results.We  had  no  data  on  death  during  the  ﬁrst  48  hours  nor  on
elay  to  reperfusion  after  index  AMI.  These  data  would  have
elped  us  to  better  ﬁne-tune  the  difference  in  prognosis
etween  NSTEMI  and  STEMI.
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onclusion
n  conclusion,  as  far  as  we  know,  our  study  is  the  ﬁrst  report
omparing  outcomes  and  eplerenone  efﬁciency  among  post-
MI  acute  systolic  HF  patients  with  STEMI  and  NSTEMI.
The  study  shows  that  in  that  speciﬁc  high-risk  popula-
ions,  NSTEMI  remains  a  useful  marker  for  identifying  a  group
f  patients  with  more  adverse  long-term  outcomes.  Among
hose  patients,  eplerenone  improves  outcomes  equally  in
TEMI  patients  and  NSTEMI  patients.  However,  because
STEMI  carries  a  worse  prognosis,  additional  therapeutic
nterventions  must  be  carried  out  in  such  high-risk  LVSD
atients,  including  more  aggressive  medical  therapies  and
ore  frequent  revascularization.
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